Tuberculosis Therapeutics Market Report 2025

This Tuberculosis Therapeutics market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The tuberculosis therapeutics market size has grown strongly in recent years. It will grow from $1.88 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 6.58%. The growth during the historical period can be attributed to the increasing incidence of tuberculosis, the rising adoption of tuberculosis therapeutics, greater awareness of tuberculosis (TB), the growing prevalence of XDR-TB, and the increasing cases of drug-resistant tuberculosis.

The tuberculosis therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.57 billion in 2029 at a compound annual growth rate (CAGR) of 6.32%. The anticipated growth in the forecast period is driven by increased investments in healthcare infrastructure, heightened awareness and education efforts, greater investment in research and development, an increase in product approvals for various anti-TB agents, expanded research funding, and a growing geriatric population. Key trends expected during this period include advancements in drug development, the rise of personalized medicine, combination therapies, integration of digital health solutions, and the use of AI and machine learning in drug discovery.

The increasing rates of TB-HIV co-infections are expected to drive the growth of the tuberculosis therapeutics market in the coming years. TB-HIV co-infection refers to individuals simultaneously infected with tuberculosis (TB) and human immunodeficiency virus (HIV). The rise in co-infections is attributed to the immune system suppression caused by HIV, which increases susceptibility to TB, along with the global overlap of these epidemics in high-risk populations. Tuberculosis therapeutics play a crucial role in addressing these co-infections by providing targeted treatments that combat TB while mitigating HIV-related immune suppression, thereby improving patient outcomes and alleviating the dual disease burden. For example, in October 2023, data from gov.uk indicated that England recorded 3,805 new HIV diagnoses in 2022, reflecting a 22% increase from the 3,118 cases reported in 2021. Such rising co-infection rates are significantly fueling the demand for tuberculosis therapeutics.

Leading companies in the tuberculosis therapeutics market are focusing on advancements such as combination therapies to enhance treatment effectiveness, shorten therapy durations, and address drug-resistant tuberculosis strains. Combination therapy utilizes two or more drugs from different classes to boost treatment efficacy, minimize resistance, and improve overall patient outcomes. For instance, in July 2024, Johnson & Johnson achieved a breakthrough with the approval of SIRTURO (bedaquiline) by the U.S. FDA and the European Commission. SIRTURO is the first drug in over 40 years specifically designed for multidrug-resistant tuberculosis (MDR-TB). By targeting the ATP synthase enzyme critical for TB bacteria's energy production, SIRTURO offers a targeted and potent treatment option. When incorporated into combination therapies, it enhances regimen efficacy, reduces treatment timelines, and promotes better patient adherence.

In May 2024, BioVersys AG, a Swiss biotechnology company, entered into a strategic partnership with GSK plc to accelerate the clinical development of alpibectir (BVL-GSK098) for tuberculosis treatment. This collaboration aims to advance innovative therapeutic solutions for TB. GSK plc, a UK-based pharmaceutical company, is known for its contributions to developing and manufacturing groundbreaking medicines, including treatments for tuberculosis.

Major players in the tuberculosis therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Macleods Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., Sequella Inc.

North America was the largest region in the tuberculosis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tuberculosis therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the tuberculosis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tuberculosis therapeutics encompass pharmaceutical treatments aimed at preventing and curing tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. These treatments focus on eradicating the bacteria, reducing transmission, and improving outcomes for patients, particularly those with drug-resistant strains.

The primary types of tuberculosis therapeutics are active tuberculosis (TB) and latent tuberculosis (TB). Active tuberculosis is a contagious bacterial infection that primarily affects the lungs, leading to symptoms such as persistent cough, fever, and weight loss. Available product types include isoniazid, rifampin, pyrazinamide, hydrazine derivatives, miscellaneous anti-tubercular drugs, and ethambutol. The treatments are administered via various routes, such as oral, parenteral, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. End users include hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.

The tuberculosis therapeutics market research report is one of a series of new reports that provides tuberculosis therapeutics market statistics, including the tuberculosis therapeutics industry global market size, regional shares, competitors with the tuberculosis therapeutics market share, detailed tuberculosis therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the tuberculosis therapeutics industry. This tuberculosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tuberculosis therapeutics market consists of sales of combination therapies, vaccines, supportive therapies, biologics, and newer drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.